Lung Cancer Treatments and Mutations
Moving in Cancer Discovery, Nature.
- Moved this week
- 5
Rebuilt
Moved this week
Next-generation tyrosine kinase inhibitor sunvozertinib shows superior efficacy over chemotherapy as a first-line treatment for EGFR exon 20 insertion non-small cell lung cancer in the phase III WU-KONG28 trial.
- In the news
Ivonescimab combined with chemotherapy improves overall survival in advanced squamous NSCLC, showing a significant benefit over existing immunotherapy-chemotherapy regimens in a Chinese trial.
- In the news
A 14-protein blood test predicts lung cancer risk over 5 years before detection, including in never-smokers outside current screening guidelines.
- In the news
Daraxonrasib, a first-in-class pan-RAS inhibitor, shrank tumors in over 30% of patients with advanced RAS-mutant non-small cell lung cancer.
- In the news
Latest in Lung Cancer Treatments and Mutations
Newest first · last 60 days
TRI-611 is the first clinical-stage molecular glue degrader targeting ALK fusion proteins, achieving tumor regression in ALK-positive NSCLC models.
A rare inherited EGFR mutation has persisted in Southern Appalachia since the 1700s, now affecting populations and increasing lung cancer risk.
Population data reveal the historical origin of a rare genetic variant linked to increased lung cancer risk.
Germline EGFR T790M mutation significantly increases lung cancer risk, especially in never-smokers, surpassing the risk from smoking in over 3.3 million individuals.
Small cell lung cancer exhibits a high 80% rate of brain metastases driven by neurotropic mechanisms and resistance to current therapies.
Virtual tumor models accurately predict personalized therapeutic combinations for NSCLC, identifying 53BP1 as a promising target and stratifying patients for radiotherapy.
Detection of molecular residual disease via circulating tumor DNA identifies high recurrence risk in resectable solid tumor patients, enabling more efficient clinical trials.
Tambotatug pelitecan significantly improves survival and response rates in relapsed small-cell lung cancer compared to topotecan, with fewer severe adverse events.
Six proteomic aging clocks consistently predicted lower biological age in a 12-week clinical trial of rentosertib for idiopathic pulmonary fibrosis.
- Open access
Heterogeneous resistance mechanisms, including EGFR mutations, bypass signaling, and transformation, emerge in EGFR T790M-positive lung adenocarcinoma after 14.2 months of osimertinib treatment.
- Open access
Small-molecule inhibitors targeting RAS/RAF disrupt allosteric RAF conformation, effectively treating diverse RAS-driven cancers with a broad-spectrum approach.
- Open access
Sunvozertinib significantly improves progression-free survival compared to chemotherapy as a first-line treatment for NSCLC with EGFR exon 20 insertions, with a median of 10.3 versus 7.5 months.
- 1 cites
Selpercatinib significantly improves 2-year event-free survival in early-stage RET fusion-positive NSCLC, reaching 92% in stage II/IIIA patients compared to 61% with placebo.
- 2 cites
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1738
- Environ Res483
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ199
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- J Exp Bot115
- Curr Biol112
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4